Press release from PR Newswire
Regeneron Announces Panel Discussion at Citi's 5th Annual Biotech Day
Tuesday, September 28, 2010
TARRYTOWN, N.Y., Sept. 28 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in a webcast panel discussion on the topic "Eye Diseases: Novel Therapies for Wet AMD, Retinal Vein Occlusion and Diabetic Macular Edema" at Citi's 5th Annual Biotech Day on Tuesday, October 5, 2010. The panel discussion will be broadcast live at 8:00 a.m. Eastern Time and may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through November 4, 2010.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.
Michael Aberman, M.D.
SOURCE Regeneron Pharmaceuticals, Inc.
For further information: Michael Aberman, M.D., Investor Relations, +1-914-345-7799, firstname.lastname@example.org, or Peter Dworkin, Corporate Communications, +1-914-345-7800, email@example.com